FindMyKOL

Elena Christofides, MD, FACE

Basic profile

Endocrinology, Diabetes & Metabolism

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionColumbus, OH · MidwestSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Active KOLEmergingFindMyKOL type: NationalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Elena Christofides is an Endocrinology/Metabolic physician. OpenAlex indexes 30 publications with 620 citations (h-index 7); ClinicalTrials.gov lists 2 registered studies matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
30publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

620citations

Citations across these publications.

7h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
2clinical trials

Investigator role on registered studies.

View trials ↓
61companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Industry payments

61 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Eli Lilly
    Program year20252 paymentsResearch
    $152,535
  • RECORDATI_RARE_DISEASES_INC.
    Program year2025107 payments
    $92,277
  • Corcept Therapeutics
    Program year202595 payments
    $90,271
All 167 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    43.7%
    GLP-1 receptor agonist14.7%
    Mounjaro37%Ozempic37%Trulicity26%
    Part D≥12 patients
    Thiazolidinedione11.7%
    Pioglitazone Hcl89%Pioglitazone-Metformin11%
    Part D<11 patients

    + 5 more classes in this area

  • Hormonal (systemic)

    23%
    l-Thyroxine14.1%
    Synthroid100%
    Part D≥47 patients
    Recombinant Human Growth Hormone4%
    Genotropin59%Omnitrope41%
    Part D<11 patients

    + 2 more classes in this area

  • Cardiovascular

    18.4%
    Statin5.2%
    Atorvastatin Calcium100%
    Part D≥20 patients
    Omega-3 / fibrate3.8%
    Omega-3 Acid Ethyl Esters100%
    Part D≥13 patients

    + 7 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”